Literature DB >> 13920820

Identification of tubercle bacilli from Indian patients with pulmonary tuberculosis.

K L THOMAS, S JOSEPH, T SUBBAIAH, J B SELKON.   

Abstract

Pretreatment cultures of bacilli from Indian patients with active pulmonary tuberculosis admitted to a controlled domiciliary chemotherapy study by the Tuberculosis Chemotherapy Centre, Madras, were subjected to a series of in vitro tests designed to identify the bacilli as human or bovine tubercle bacilli, or as anonymous mycobacteria. For the purposes of comparison, pretreatment cultures from British patients with pulmonary tuberculosis were examined by the same series of identification tests.Cultures identifiable as mammalian tubercle bacilli were obtained from all the 341 Indian patients admitted to the chemotherapy study. Tests for niacin production were carried out on the cultures from 277 of these patients; all gave positive results, indicating that the bacilli in question were Mycobacterium tuberculosis var. hominis. The cultures from the Indian patients yielded results similar to those of the cultures from the British patients in all the in vitro tests except the thiacetazone-sensitivity test. In this test the Indian cultures differed from the British cultures, being on the average less sensitive and showing greater variation in sensitivity among themselves.

Entities:  

Keywords:  TUBERCULOSIS, PULMONARY/microbiology

Mesh:

Year:  1961        PMID: 13920820      PMCID: PMC2555626     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  15 in total

1.  Combined drug treatment of tuberculosis. I. Prevention of emergence of mutant populations of tubercle bacilli resistant to both streptomycin and isoniazid in vitro.

Authors:  M L COHN; G MIDDLEBROOK; W F RUSSELL
Journal:  J Clin Invest       Date:  1959-08       Impact factor: 14.808

2.  Morphological and biochemical features of 'atypical' mycobacteria.

Authors:  A CSILLAG
Journal:  J Gen Microbiol       Date:  1961-02

3.  Anonymous mycobacteria in pulmonary disease.

Authors:  E H RUNYON
Journal:  Med Clin North Am       Date:  1959-01       Impact factor: 5.456

4.  A comparison of the virulence in guinea-pigs of South Indian and British tubercle bacilli.

Authors:  D A MITCHISON; J G WALLACE; A L BHATIA; J B SELKON; T V SUBBAIAH; M C LANCASTER
Journal:  Tubercle       Date:  1960-02

5.  Human infection with the yellow acid-fast bacillus; a report of fifteen additional cases.

Authors:  L E WOOD; V B BUHLER; A POLLAK
Journal:  Am Rev Tuberc       Date:  1956-06

6.  A limited clinical, pathologic, and epidemiologic study of patients with pulmonary lesions associated with atypical acid-fast bacilli in the sputum.

Authors:  H E CROW; C T KING; C E SMITH; R F CORPE; I STERGUS
Journal:  Am Rev Tuberc       Date:  1957-02

7.  Arylsulphatase activity of mycobacteria.

Authors:  J E WHITEHEAD; P WILDY; H C ENGBAEK
Journal:  J Pathol Bacteriol       Date:  1953-04

8.  The virulence in the guinea-pig of tubercle bacilli isolated before treatment from South Indian patients with pulmonary tuberculosis. I. Homogeneity of the investigation and a critique of the virulence test.

Authors:  D A MITCHISON; A L BHATIA; S RADHAKRISHNA; J B SELKON; T V SUBBAIAH; J G WALLACE
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

9.  A comparison of the sensitivity to p-aminosalicylic acid of tubercle bacilli from South Indian and British patients.

Authors:  J B SELKON; T V SUBBAIAH; A L BHATIA; S RADHAKRISHNA; D A MITCHISON
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

10.  VIRULENCE AND MORPHOLOGICAL CHARACTERISTICS OF MAMMALIAN TUBERCLE BACILLI.

Authors:  G Middlebrook; R J Dubos; C Pierce
Journal:  J Exp Med       Date:  1947-07-31       Impact factor: 14.307

View more
  7 in total

1.  The virulence in the guinea-pig of isoniazid-sensitive tubercle bacilli isolated from South Indian patients before treatment and after three months of chemotherapy.

Authors:  T V SUBBAIAH; A L BHATIA; E GERAGHTY; D A MITCHISON; S RADHAKRISHNA; J B SELKON
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

2.  [Comparative study of 2 types of oral therapy of pulmonary tuberculosis (ethionamide and isoniazid, thiacetazone and isoniazid)].

Authors:  F J Chicou; G Hétrick; M Huet; H Radenac; N Rist
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

3.  Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes.

Authors:  G Canetti; W Fox; A Khomenko; H T Mahler; N K Menon; D A Mitchison; N Rist; N A Smelev
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

4.  Two controlled studies of the efficacy of isoniazid alone in preventing relapse in patients with bacteriologically quiescent pulmonary tuberculosis at the end of one year of chemotherapy.

Authors:  O Nazareth; S Devadatta; W Fox; N K Menon; S Radhakrishna; D Rajappa; C V Ramakrishnan; P R Somasundaram; H Stott; S Subbammal; S Velu
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

5.  A COMPARISON OF THE VIRULENCE IN THE GUINEA-PIG OF TUBERCLE BACILLI FROM THAI AND BRITISH PATIENTS.

Authors:  A L BHATIA; C V JACOB; K L HITZE; K RAMACHANDRAN; J B SELKON
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

6.  Response of patients infected with isoniazid-resistant tubercle bacilli to treatment with isoniazid plus PAS or isoniazid alone.

Authors:  S DEVADATTA; A L BHATIA; R H ANDREWS; W FOX; D A MITCHISON; S RADHAKRISHNA; C V RAMAKRISHNAN; J B SELKON; S VELU
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

7.  High clustering rates of multidrug-resistant Mycobacterium tuberculosis genotypes in Panama.

Authors:  Samantha Rosas; Jaime Bravo; Franklin Gonzalez; Nora de Moreno; Joel Sanchez; Ronnie G Gavilan; Amador Goodridge
Journal:  BMC Infect Dis       Date:  2013-09-23       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.